NYSE: BMY
BRISTOL MYERS SQUIBB COCIK 0000014272 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (WCN 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade BMY commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Jul 30, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Earnings (Unaudited)
Dollars in millions
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Net product sales | 12,588 | 11,909 | 23,756 | 22,794 |
| Alliance and other revenues | 385 | 360 | 706 | 676 |
| Total Revenues | 12,973 | 12,269 | 24,462 | 23,470 |
| Cost of products sold(a) | 3,726 | 3,372 | 7,146 | 6,404 |
| Selling, general and administrative | 1,826 | 1,713 | 3,443 | 3,297 |
| Research and development | 2,959 | 2,580 | 5,608 | 4,837 |
| Acquired IPRD | — | 1,508 | 94 | 1,695 |
| Amortization of acquired intangible assets | 437 | 830 | 874 | 1,660 |
| Other (income)/expense, net | (61) | 494 | (28) | 833 |
| Total Expenses | 8,887 | 10,496 | 17,137 | 18,726 |
| Earnings/(Loss) before income taxes | 4,086 | 1,773 | 7,326 | 4,744 |
| Income tax provision | 770 | 460 | 1,331 | 969 |
| Net earnings/(loss) | 3,316 | 1,313 | 5,994 | 3,775 |
| Noncontrolling interest | (1) | 2 | — | 9 |
| Net earnings/(loss) attributable to BMS | 3,317 | 1,310 | 5,994 | 3,766 |
| Earnings/(Loss) per common share: | ||||
| Basic | 1.62 | 0.64 | 2.94 | 1.85 |
| Diluted | 1.62 | 0.64 | 2.93 | 1.85 |
Consolidated Balance Sheets (Unaudited)
Dollars in millions
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 8,722 | 10,209 |
| Marketable debt securities | 2,345 | 464 |
| Receivables | 10,553 | 11,414 |
| Inventories | 2,737 | 2,690 |
| Other current assets | 4,222 | 4,613 |
| Total Current assets | 28,579 | 29,390 |
| Property, plant and equipment | 7,791 | 7,543 |
| Goodwill | 21,740 | 21,754 |
| Other intangible assets | 17,387 | 19,103 |
| Deferred income taxes | 5,362 | 5,378 |
| Marketable debt securities | 397 | 396 |
| Other non-current assets | 6,378 | 6,474 |
| Total Assets | 87,634 | 90,038 |
| LIABILITIES | ||
| Current liabilities: | ||
| Short-term debt obligations | 1,027 | 2,261 |
| Accounts payable | 4,158 | 3,575 |
| Other current liabilities | 13,474 | 17,581 |
| Total Current liabilities | 18,659 | 23,417 |
| Deferred income taxes | 222 | 222 |
| Long-term debt | 42,093 | 42,850 |
| Other non-current liabilities | 4,341 | 5,043 |
| Total Liabilities | 65,315 | 71,533 |
| Commitments and Contingencies (see Note 18) | ||
| EQUITY | ||
| BMS Shareholders’ equity: | ||
| Preferred stock | — | — |
| Common stock | 292 | 292 |
| Capital in excess of par value of stock | 46,504 | 46,387 |
| Accumulated other comprehensive loss | (1,290) | (1,524) |
| Retained earnings | 20,316 | 16,896 |
| Less cost of treasury stock | (43,504) | (43,579) |
| Total BMS Shareholders’ equity | 22,319 | 18,473 |
| Noncontrolling interest | — | 33 |
| Total Equity | 22,319 | 18,506 |
| Total Liabilities and Equity | 87,634 | 90,038 |
Consolidated Statements of Cash Flows (Unaudited)
Dollars in millions
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash Flows From Operating Activities: | ||
| Net earnings/(loss) | 5,994 | 3,775 |
| Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities: | ||
| Depreciation and amortization, net | 1,188 | 2,023 |
| Deferred income taxes | (34) | (214) |
| Stock-based compensation | 281 | 281 |
| Impairment charges | 834 | 318 |
| Divestiture gains and royalties | (176) | (585) |
| Acquired IPRD | 94 | 1,695 |
| Equity investment (gains)/losses, net | (248) | 100 |
| Contingent consideration fair value adjustments | — | 336 |
| Other adjustments | 22 | (2) |
| Changes in operating assets and liabilities: | ||
| Receivables | 504 | (469) |
| Inventories | (22) | (165) |
| Accounts payable | 380 | (72) |
| Rebates and discounts | (3,135) | 254 |
| Income taxes payable | (335) | (567) |
| Other | (850) | (837) |
| Net cash provided by operating activities | 4,497 | 5,871 |
| Cash Flows From Investing Activities: | ||
| Sale and maturities of marketable debt securities | 964 | 744 |
| Purchase of marketable debt securities | (2,851) | (1,257) |
| Proceeds from sales of equity investments | 429 | 12 |
| Capital expenditures | (652) | (621) |
| Divestiture and other proceeds | 521 | 513 |
| Acquisition and other payments, net of cash acquired | (156) | (363) |
| Net cash provided by/(used in) investing activities | (1,745) | (972) |
| Cash Flows From Financing Activities: | ||
| Other short-term financing obligations, net | 191 | 426 |
| Repayments of long-term debt | (1,720) | (643) |
| Dividends | (2,570) | (2,520) |
| Stock option proceeds and other, net | (91) | (92) |
| Net cash provided by/(used in) financing activities | (4,190) | (2,829) |
| Effect of exchange rates on cash, cash equivalents and restricted cash | (58) | 194 |
| Increase/(decrease) in cash, cash equivalents and restricted cash | (1,496) | 2,264 |
| Cash, cash equivalents and restricted cash at beginning of period | 10,218 | 10,347 |
| Cash, cash equivalents and restricted cash at end of period | 8,722 | 12,611 |
Amounts as printed on the EDGAR/iXBRL face — Dollars in millions. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗